Preoperative serum levels of matrix metalloproteinase-2 (MMP-2) and survival of breast cancer among Korean women

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 8, 2012, Pages 1371-1380

  Song, Nan ^a   Sung, Hyuna ^c   Choi, Ji Yeob ^a,c   Han, Sohee ^a   Jeon, Sujee ^d   Song, Minkyo ^a,c   Lee, Yunhee ^c   Park, Chulbum ^c   Park, Sue K ^a,c   Lee, Kyoung Mu ^e   Yoo, Keun Young ^a   Noh, Dong Young ^a,b   Ahn, Sei Hyun ^f   Lee, Sang Ah ^f   Kang, Daehee ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Korea National Open University   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Kangwon National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; GELATINASE A; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PROGNOSIS; REPUBLIC OF KOREA; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864810176     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0293     Document Type: Article

References (45)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al., editors. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. [cited Sep 15, 2011]. Available from: http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
2. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008;107:309-30. (Pubitemid 351172108)
3. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
4. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7. (Pubitemid 32223594)
5. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40. (Pubitemid 32817010)
6. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66. (Pubitemid 34309470)
7. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23. (Pubitemid 32591662)
8. Guo CB, Wang S, Deng C, Zhang DL, Wang FL, Jin XQ. Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther 2007;11:183-92. (Pubitemid 46983410)
9. Sasaki H, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y. Elevated serum pro-mMP2 levels in patients with advanced lung cancer are not suitable as a prognostic marker. Surg Today 2002;32:93-5. (Pubitemid 34119058)
10. Wollina U, Hipler UC, Knoll B, Graefe T, Kaatz M, Kirsch K.Serum matrix metalloproteinase-2 in patients with malignant melanoma. J Cancer Res Clin Oncol 2001;127:631-5. (Pubitemid 32778654)
11. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de e Nictolis M, Garbisa S, et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 1995;15:2799-804. (Pubitemid 26095103)
12. Sasaki H, Yukiue H, Kobayashi Y, Kaji M, Kiriyama M, Fukai I, et al. Elevated serum pro-MMP2 levels in patients with stage IV thymoma. Surg Today 2002;32:482-6. (Pubitemid 34810731)
13. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, et al. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78:2379-87. (Pubitemid 26392839)
14. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 1998;77:650-5. (Pubitemid 28059475)
15. Aref S, Osman E, Mansy S, Omer N, Azmy E, Goda T, et al.Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients. Hematol Oncol 2007;25:121-6. (Pubitemid 47507879)
16. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20:1085-91. (Pubitemid 30240680)
17. Hanke B, Wein A, Martus P, Riedel C, Voelker M, Hahn EG, et al.Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br J Cancer 2003;88:1248-50. (Pubitemid 36606341)
18. Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006;94:1035-40.
19. Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J. Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol 2012;29:561-9.
20. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003;89:1270-5. (Pubitemid 37363416)
21. Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat 2003;77:85-91. (Pubitemid 36182919)
22. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004;88:75-85. (Pubitemid 39524447)
23. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-62. (Pubitemid 28419068)
24. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008;19:1566-72.
25. Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007;96:903-11. (Pubitemid 46452295)
26. Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract 2010;206:241-7.
27. Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, Lee CY, et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta 2006;371:92-6.
28. Sheen-Chen SM, Chen HS, Eng HL, Sheen CC, Chen WJ. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 2001;173:79-82.
29. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004;90:1414-21. (Pubitemid 38586271)
30. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, et al. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006;119:1403-11. (Pubitemid 44258818)
31. Sliwowska I, Kopczynski Z. [Zymography-method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer]. Wiad Lek 2007;60:241-7.
32. Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, et al. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res 2007;27:3593-600. (Pubitemid 47610486)
33. Vinothini G, Aravindraja C, Chitrathara K, Nagini S. Correlation of matrix metalloproteinases and their inhibitors with hypoxia and angiogenesis in premenopausal patients with adenocarcinoma of the breast. Clin Biochem 2011;44:969-74.
34. Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem 2011;44:869-72.
35. Lv M, Xiaoping X, Cai H, Li D, Wang J, Fu X, et al. Cytokines as prognostic tool in breast carcinoma. Front Biosci 2012;17:2515-26.
36. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004;10:1057-63. (Pubitemid 38198907)
37. Kuvaja P, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma. Hum Pathol 2006;37:1316-23. (Pubitemid 44380276)
38. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 2003;252:305-29. (Pubitemid 37220762)
39. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4. (Pubitemid 129519680)
40. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 2003;162:391-402. (Pubitemid 36267847)
41. Elliot S, Catanuto P, Fernandez P, Espinosa-Heidmann D, Karl M, Korach K, et al. Subtype specific estrogen receptor action protects against changes in MMP-2 activation in mouse retinal pigmented epithelial cells. Exp Eye Res 2008;86:653-60.
42. Giannelli G, Erriquez R, Fransvea E, Daniele A, Trerotoli P, Schittulli F, et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004;109:782-5. (Pubitemid 38405629)
43. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67:1126-31. (Pubitemid 23147516)
44. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I.Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res Treat 2005;90:117-25. (Pubitemid 40568895)
45. Lewandowski KC, Komorowski J, Mikhalidis DP, Bienkiewicz M, Tan BK, O'Callaghan CJ, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006;91:3123-30. (Pubitemid 44271767)